Insmed, Inc.

Insmed, Inc.

Insmed, Inc.

Overview
Date Founded

1988

Headquarters

10 Finderne Avenue,Building 10,Bridgewater, NJ 08807-3365

Type of Company

Public

Employees (Worldwide)

521

Industries

Wholesale: Consumer Non-Durables/Sundries
Pharmaceuticals
Medical Support Services
Biotechnology

Company Description

Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Contact Data
Trying to get in touch with decision makers at Insmed, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chair & Chief Executive Officer

Chief Financial Officer & Principal Accounting Officer

Chief Operating Officer

General Counsel, Senior Vice President

Chief Technology Officer

Chief Compliance Officer

Chief Business Officer & Executive Vice President

Chief People Strategy Officer

Chief Accounting Officer

Chief Medical Officer

Board of Directors

Chair & Chief Executive Officer at Insmed, Inc.

Principal at PureSight Advisory LLC

Former Chief Executive Officer & Executive Director at AstraZeneca Plc

Former President, Chief Executive Officer & Director at CEPMED

Executive Officer, Director at Adolor Corp.

Managing Partner at Hyphen Advisors LLC

Former President at Actavis, Inc.

President at Merck Serono Co., Ltd.

Director-Charles D Close School at Drexel University

Chairman & Chief Executive Officer at Engelsen Invest AS

Paths to Insmed, Inc.
Potential Connections via
Relationship Science
You
Insmed, Inc.
Owners & Shareholders
Details Hidden

Palo Alto Investors, LLC (PAI) is a leading private investment firm. We make long-term investments for high-net-worth and institutional investors based on original, deep, fundamental research. We don’t rent stocks. We own them. With approximately $900 million in assets under management, we offer a diversified micro cap fund and healthcare sector funds. Significant partner ownership in all of our Funds serves to align our financial interests with the financial interests of our clients. At PAI our mission is to deliver superior returns to our clients by investing for the long term. At the core of our investment philosophy lies the belief that intensive, original research is required to discover and evaluate inefficiently priced equities. We generally focus our investments in micro cap and small cap U.S. equities, which are not closely followed by Wall Street sell-side research firms. We target overlooked, misunderstood and undervalued segments of the equity markets, such as healthcare, energy and technology that have significant potential for appreciation. Our experienced research team has extensive industry experience in the sectors they cover. They utilize a disciplined, bottom-up approach to identify promising investments, and the firm’s investment policies ensure liquidity horizons that are sufficient to take advantage of new opportunities. PAI is committed to providing exemplary client service, maintaining the highest level of ethics, operational excellence and professionalism. PAI is independently owned, and has been registered with the SEC since its inception in 1989

Details Hidden

Bellevue AM is an active, fundamental research-based manager which utilizes a bottom-up investment and anti-cyclical approach that aims to generate above-average returns while keeping risk under control and well monitored. They screen and invest in promising family and owner-managed companies based in Switzerland or the broader European continent through our family of Entrepreneur funds. The firm has become very adept at identifying high growth potential in new and emerging markets, particularly on the African continent.

Details Hidden

SCL uses a variety of investment strategies and has broad discretion in making investments for the Funds. The firm draws on numerous resources to generate ideas, including public financial statements, industry conferences, traditional Wall Street research and industry contacts, consultants and bankers. Research typically includes reviewing the prospectus of the company and conducting an analysis of a company’s reported earnings as well as financial statements and SEC filings. They develop and closely reviews internal valuations for potential investment targets, including revenues, margins, operating income, cash flow and earnings per share.

Recent Transactions
Details Hidden

Insmed, Inc. issued USD Common Stock

Details Hidden

Insmed, Inc. issued USD Common Stock

Details Hidden

Insmed, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Legal Advisor

Advised onInsmed, Inc. issued USD Common Stock

Underwriter

Advised onInsmed, Inc. issued USD Common Stock

Underwriter

Advised onInsmed, Inc. issued USD Common Stock

Legal Advisor

Advised onInsmed, Inc. issued USD Common Stock

Underwriter

Advised onInsmed, Inc. issued USD Common Stock

Professional

Advised onInsmed, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Shareholder at Greenberg Traurig LLP

Legal Advisor

Shareholder at Greenberg Traurig LLP

Consultant

Executive Vice President, Chief Financial & Accounting Officer at Turning Point Therapeutics, Inc.

Key Stats and Financials As of 2020
Market Capitalization
$3.21B
Total Enterprise Value
$3.12B
Earnings Per Share
$-3.01
Revenue
$164M
Net Profit
$-294M
EBITDA
$-245M
EBITDAMargin
-149.11%
Total Debt
$405M
Total Equity
$276M
Enterprise Value / Sales
18.98x
TEVNet Income
-10.61x
Debt TEV
0.13x
Suppliers
Ajinomoto Co., Inc. Industrial Machinery & Manufacturing | Tokyo, Japan

Ajinomoto Co., Inc. engages in the manufacture, distribution, and sale of food products, amino acids, and pharmaceuticals. It operates through the following segments: Seasoning and Foods, Frozen Foods, Healthcare and Others, and Others. The Seasoning and Foods segment offers spices such as Ajinomoto, Cook Do, Ros Dee, Masako, Aji-ngon, Sazon, SAJIKU, and CRISPY FRY. It also provides nutritional and processed food such as Knorr Cup Soup, YumYum, Blendy, and MAXIM brand products. It also covers ingredients for processed food, bakery products, beverages, and sweeteners. The Frozen Foods segment sells dumplings, rice, noodles, desserts, and processed chicken products. The Healthcare and Others segment deals with amino acids for pharmaceuticals, nutritional food, cosmetic materials, and chemical products. It also handles biopharmaceutical services. The Others segment includes contract manufacturing business, oil and fat-related business, logistics, and other services. The company was founded by Saburosuke Suzuki II on May 20, 1909 and is headquartered in Tokyo, Japan.

Therapure Biopharma, Inc. Pharmaceuticals | Mississauga, Canada

Therapure Biopharma, Inc. engages in the business of contract development and manufacturing. It operates through the following divisions: Therapure Biomanufacturing, Therapure Innovations, and Evolve Biologics. The Therapure Biomanufacturing division focuses on contract development and manufacturing of complex biologics. The Therapure Innovations division includes in-house proprietary-drug development. The Evolve Biologics division develops a portfolio of plasma-derived pharmaceutical products. The company was founded in 2008 and is headquartered in Mississauga, Canada.

Pari Medical Holding GmbH Medical Products & Equipment | Starnberg, Germany

PARI MEDICAL HOLDING GmbH is a private company headquartered in Starnberg, Germany, with operations in Germany and the United Kingdom, that manufactures and markets medical inhalation systems. It was founded in 2004. Johann Zimmermann, Martin Knoch and Juergen Mueller are the current co-CEOs of the company.The company says this about itself: PARI Medical Holding GmbH (Starnberg, Germany): Strategic services for the departments Finance, IT, QM and Regulatory Affairs within the PARI Group. As the umbrella organisation PARI Medical Holding coordinates the international objectives and activities of the PARI Group. It is responsible for providing strategic services to the departments dealing with finance, information technology, quality management and the licensing of medical devices.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Insmed, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Insmed, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Insmed, Inc..